Home » Stocks » CDTX

Cidara Therapeutics, Inc. (CDTX)

Stock Price: $2.29 USD 0.02 (0.88%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Pre-market: $2.30 +0.01 (0.44%) Mar 2, 4:06 AM
Market Cap 102.60M
Revenue (ttm) 12.07M
Net Income (ttm) -74.87M
Shares Out 41.56M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $2.29
Previous Close $2.27
Change ($) 0.02
Change (%) 0.88%
Day's Open 2.30
Day's Range 2.21 - 2.37
Day's Volume 665,855
52-Week Range 1.30 - 4.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

GlobeNewsWire - 2 months ago

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs Former head of commercial API manufa...

GlobeNewsWire - 3 months ago

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

Zacks Investment Research - 3 months ago

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care fo...

Zacks Investment Research - 4 months ago

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care...

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for pati...

Zacks Investment Research - 6 months ago

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -87.50% and -79.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 7 months ago

SAN DIEGO, July 17, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patie...

GlobeNewsWire - 9 months ago

SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the stan...

Zacks Investment Research - 9 months ago

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 9 months ago

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patien...

GlobeNewsWire - 9 months ago

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020

Zacks Investment Research - 9 months ago

Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 11 months ago

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 11 months ago

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -44.83% and -83.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 1 year ago

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing sev...

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering...

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approxima...

InvestorPlace - 1 year ago

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

Other stocks mentioned: CPE, KDMN, NEX, OVID, QEP
GlobeNewsWire - 1 year ago

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020

GlobeNewsWire - 1 year ago

Employee feedback places Cidara among top small companies in the area Employee feedback places Cidara among top small companies in the area

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced tha...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced th...

24/7 Wall Street - 1 year ago

Earlier this week, Cidara Therapeutics Inc. (NASDAQ: CDTX) announced a huge deal that catapulted the stock up nearly 50%.

Benzinga - 1 year ago

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin.

Benzinga - 1 year ago

Cidara Therapeutics Inc (NASDAQ: CDTX) shares were advancing by more than 50% Tuesday after the thinly traded, micro-cap biotech announced a development and commercialization deal for its lead...

Market Watch - 1 year ago

Shares of Cidara Therapeutics Inc. CDTX, +0.00% rocketed 67% in active premarket trading Tuesday, after the biotechnology company announced a partnership with Mundipharma with a total potentia...

About CDTX

Cidara Therapeutics, a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral F... [Read more...]

Industry
Biotechnology
IPO Date
Apr 15, 2015
CEO
Jeffrey Stein
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
CDTX
Full Company Profile

Financial Performance

In 2020, CDTX's revenue was $12.07 million, a decrease of -42.30% compared to the previous year's $20.92 million. Losses were -$72.11 million, 75.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is 6.40, which is an increase of 179.48% from the latest price.

Price Target
$6.40
(179.48% upside)
Analyst Consensus: Buy